{"id":"NCT03061812","sponsor":"AbbVie","briefTitle":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","officialTitle":"A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-11","primaryCompletion":"2020-02-12","completion":"2020-02-12","firstPosted":"2017-02-23","resultsPosted":"2021-02-23","lastUpdate":"2021-02-23"},"enrollment":444,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Rovalpituzumab tesirine","otherNames":["Rova-T"]},{"type":"DRUG","name":"Topotecan","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Rovalpituzumab tesirine","type":"EXPERIMENTAL"},{"label":"Topotecan","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization until the end of study; median time on follow-up was 20 and 20.6 months for the topotecan and rovalpituzumab tesirine arms, respectively.","effectByArm":[{"arm":"Topotecan","deltaMin":8.57,"sd":null},{"arm":"Rovalpituzumab Tesirine","deltaMin":6.34,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0051"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":195,"countries":["United States","Australia","Belarus","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Japan","Latvia","Mexico","Netherlands","Poland","Portugal","Romania","Russia","Serbia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["31506387","29290251"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":129},"commonTop":["ANAEMIA","DECREASED APPETITE","NAUSEA","FATIGUE","THROMBOCYTOPENIA"]}}